Interventional Radiology Imaging

What Imaging Is Best for Initial Staging of Adult Ocular Melanoma? An ACR-Guided Workflow

·
What Imaging Is Best for Initial Staging of Adult Ocular Melanoma? An ACR-Guided Workflow

An ophthalmologist refers a 68-year-old patient to your clinic following a new diagnosis of choroidal melanoma. The primary tumor has been characterized, and the patient is now scheduled for local therapy. Before treatment can begin, you must perform a systemic staging workup to assess for distant metastatic disease, which will fundamentally alter the management plan. You review the patient’s chart and consider the most effective imaging strategy. What is the first and best study to order to detect the most common sites of metastasis for this specific cancer? According to the American College of Radiology (ACR) Appropriateness Criteria, an `MRI abdomen and pelvis without and with IV contrast` is rated Usually Appropriate for this exact clinical scenario.

Who Fits This Clinical Scenario for Ocular Melanoma Staging?

This guidance is specifically for the initial systemic staging of an adult patient with a newly diagnosed ocular melanoma, most commonly uveal melanoma (including choroidal, ciliary body, or iris melanoma). The key inclusion criteria are a confirmed primary intraocular tumor and the need for a baseline evaluation for distant metastatic disease before definitive local treatment (such as plaque brachytherapy, proton beam radiation, or enucleation).

This workflow does not apply to several similar-sounding but distinct clinical situations. It is crucial to distinguish this scenario from:

  • Cutaneous or Muco-cutaneous Melanoma: These malignancies have a different pattern of spread, often involving lymphatic pathways first. Their staging algorithms are covered in separate ACR Appropriateness Criteria variants.
  • Recurrent Ocular Melanoma: Patients with a history of treated ocular melanoma who now have signs or symptoms concerning for recurrence or metastasis require a different imaging strategy, detailed in its own specific ACR variant.
  • Follow-up or Surveillance Imaging: This article addresses the initial staging. The imaging strategy for routine surveillance after initial treatment is a separate clinical question.

Applying this guidance to the wrong patient population can lead to suboptimal imaging choices and potentially miss key diagnostic information.

What Diagnoses Are You Working Up in This Scenario?

Unlike cutaneous melanoma, which often spreads via lymphatic channels, ocular melanoma spreads almost exclusively through the bloodstream (hematogenously). The imaging workup is therefore tailored to detect metastatic disease in the specific organs this cancer is known to target. The primary goal is to identify or rule out distant metastases, which are present in a small percentage of patients at initial diagnosis but have profound prognostic implications.

Hepatic Metastases
The liver is, by a significant margin, the most common site of metastasis for uveal melanoma. It is the first and often only site of distant spread in approximately 50% of patients who develop metastases. The liver’s unique dual blood supply and sinusoidal structure are thought to create a favorable microenvironment for circulating tumor cells. Consequently, high-resolution imaging of the liver is the cornerstone of the initial staging workup.

Pulmonary Metastases
The lungs are the second most common site of distant disease. While less frequent than liver involvement, pulmonary metastases are a key finding to identify during the initial workup. Their presence would classify the patient as having Stage IV disease and necessitate a systemic therapy approach.

Brain Metastases
Central nervous system (CNS) involvement is less common at initial presentation but is a critical diagnosis to make. Brain metastases can occur, and their detection is particularly important in patients with high-risk features of the primary tumor (e.g., large size, ciliary body involvement, specific genetic markers like monosomy 3) or neurologic symptoms.

Bone and Other Distant Metastases
Metastases to bone, skin, or other distant sites are also possible but are less common than those in the liver or lungs. A comprehensive staging evaluation aims to provide a full-body assessment to catch these less frequent but clinically significant sites of disease.

Why Is MRI of the Abdomen and Pelvis the Recommended First Study?

For the initial staging of adult ocular melanoma, the ACR designates `MRI abdomen and pelvis without and with IV contrast` as Usually Appropriate. This recommendation is driven by the tumor’s strong predilection for the liver and MRI’s superior ability to detect and characterize hepatic lesions.

MRI offers excellent soft tissue contrast, making it highly sensitive for identifying small liver metastases that might be missed on other modalities. The use of intravenous gadolinium-based contrast agents, often with multiphasic imaging (including arterial, portal venous, and delayed phases), allows for detailed characterization of suspicious lesions. This helps differentiate small metastases from benign findings like cysts or hemangiomas, reducing the need for follow-up studies or invasive biopsies. As a non-ionizing radiation modality (adult RRL=O 0 mSv), it avoids radiation exposure, a key consideration for baseline imaging that may be repeated for surveillance over the patient’s lifetime.

While MRI of the abdomen and pelvis is the primary recommendation, two other studies are also rated Usually Appropriate and play complementary roles:

  • FDG-PET/CT whole body: This study is excellent for detecting unexpected or widespread metastatic disease. Its strength lies in providing a comprehensive, whole-body metabolic survey. However, it involves significant radiation exposure (adult RRL=☢☢☢☢ 10-30 mSv) and may have lower sensitivity for certain small or low-avidity liver metastases compared to a dedicated liver MRI.
  • MRI head without and with IV contrast: This is the preferred study for evaluating the brain for metastases. It is often performed in conjunction with abdominal imaging, particularly for patients with high-risk primary tumors.

In contrast, other common imaging studies are rated lower for this specific purpose. For example, `CT abdomen and pelvis with IV contrast` is rated May be appropriate. While it is faster and more widely available than MRI, it has lower sensitivity for small liver metastases and involves ionizing radiation (adult RRL=☢☢☢ 1-10 mSv). Studies like `MRI abdomen and pelvis without IV contrast` are rated Usually not appropriate because the lack of contrast significantly limits the ability to detect and characterize the very hepatic lesions the test is meant to find.

What’s Next After MRI? Downstream Workflow

The results of the initial staging MRI will guide the subsequent clinical pathway. The decision tree branches based on whether the findings are positive, negative, or indeterminate for metastatic disease.

If the MRI is positive for metastatic disease:
A finding consistent with metastatic disease, most commonly in the liver, confirms a diagnosis of Stage IV ocular melanoma. The next step is typically a multidisciplinary tumor board discussion involving medical oncology, radiation oncology, interventional radiology, and ophthalmology. A biopsy of a metastatic lesion may be pursued to confirm the diagnosis histologically and obtain tissue for molecular testing (e.g., for GNAQ/GNA11 mutations), which can guide systemic therapy choices. The patient’s treatment plan will shift from local eye therapy to systemic treatment, which may include immunotherapy, targeted therapy, or liver-directed therapies.

If the MRI is negative for metastatic disease:
A negative staging MRI indicates no evidence of distant disease (Stage I, II, or III, depending on the primary tumor characteristics). The patient can proceed with the planned local therapy for the primary ocular tumor. Following treatment, the patient will enter a surveillance program, which typically involves periodic imaging to monitor for the development of future metastases.

If the MRI is indeterminate:
Occasionally, the MRI may reveal small, nonspecific lesions (e.g., in the liver) that cannot be definitively characterized as benign or malignant. In this situation, the next step depends on the level of suspicion. Options include a short-interval follow-up MRI to assess for stability or growth, or proceeding with a complementary imaging modality like `FDG-PET/CT whole body` (Usually Appropriate), which can provide metabolic information to help clarify the nature of the indeterminate finding.

Pitfalls to Avoid (and When to Get Help)

In the initial staging of ocular melanoma, several common pitfalls can compromise the diagnostic yield and delay appropriate care. Be mindful of the following:

  • Ordering a non-contrast study: An MRI of the abdomen without IV contrast is rated Usually not appropriate for good reason. It severely limits the detection and characterization of liver metastases, which is the primary goal of the exam. Always specify “without and with IV contrast.”
  • Substituting CT for MRI without clear reason: While CT is faster, its lower sensitivity for small liver metastases makes MRI the superior choice. Only substitute CT if MRI is contraindicated (e.g., incompatible implanted device, severe claustrophobia) or unavailable in a timely manner.
  • Neglecting brain imaging in high-risk cases: For patients with large primary tumors or other high-risk features, failing to perform a baseline brain MRI can miss asymptomatic CNS metastases.
  • Misinterpreting benign liver lesions: Small hepatic cysts and hemangiomas are common incidental findings. Over-calling these as metastases can lead to unnecessary anxiety and invasive procedures. Ensure review by a radiologist experienced in liver imaging.

If the imaging results are equivocal or conflict with the clinical picture, escalation to a multidisciplinary tumor board is the most appropriate next step.

Related ACR Topics and Tools

The ACR Appropriateness Criteria are a powerful resource for evidence-based imaging decisions. For a comprehensive overview of all clinical variants related to melanoma, including cutaneous and recurrent disease, please consult the main topic guide. For tools to help implement these recommendations, see the resources below.

Frequently Asked Questions

Why is liver imaging so critical in the initial staging of ocular melanoma?

The liver is the most common site for metastasis from ocular melanoma, with studies showing it is the first site of spread in a majority of patients who develop distant disease. Therefore, a high-quality examination of the liver with a modality like contrast-enhanced MRI is the highest-yield component of the initial staging workup.

Should every patient with ocular melanoma get a brain MRI at diagnosis?

Not necessarily, but it is rated *Usually Appropriate* by the ACR. It is most strongly indicated for patients with high-risk features of the primary tumor (e.g., large size, ciliary body involvement, extrascleral extension, or high-risk genetic profiles like monosomy 3) or for those with any neurologic symptoms. The decision is often made in consultation with the treating ophthalmologist and oncologist.

Is a chest X-ray sufficient to screen for lung metastases?

No. A chest radiograph is rated *Usually not appropriate* for this indication. While the lungs are the second most common site of metastasis, a chest X-ray lacks the sensitivity to detect small nodules. If a whole-body survey is desired, an FDG-PET/CT provides a much more sensitive evaluation of the lungs and other potential sites of disease.

What if my patient has a contraindication to MRI, like a pacemaker?

If a patient has an absolute contraindication to MRI, the next best alternative is `CT abdomen and pelvis with IV contrast`, which is rated *May be appropriate*. While it has lower sensitivity for small liver lesions compared to MRI, it is a reasonable alternative when necessary. The patient’s specific contraindication should be confirmed, as many modern pacemakers and other devices are now MRI-conditional.

Does the size of the primary ocular tumor affect the choice of staging imaging?

Yes, it influences the *extent* of imaging. While abdominal MRI is recommended for virtually all patients, the decision to add a brain MRI or a whole-body FDG-PET/CT is often driven by the risk profile of the primary tumor. Larger tumors (e.g., greater than 15 mm in diameter or 10 mm in thickness) confer a higher risk of metastasis, strengthening the rationale for a more comprehensive baseline staging evaluation.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026